Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-85
SponsorNational Defense Medical Center, Taiwan

About this trial

Our study aimed to use an AF-predict AI-ECG alert system to help physicians identify patients who need to wear a continuous cardiac rhythm monitor for new diagnoses of atrial fibrillation (AF), atrial flutter (AFL), or atrial arrhythmia with high AF risk, including premature atrial complexes (PAC) ≥ 500/24hr, burst PACs \> 20 beats, non-sustained AF/AFL.

Eligibility criteria

Qualifiers

Patients in the inpatient department or the outpatient department

Patients need to have at least one electrocardiogram within one year

Disqualifiers

Diagnosis of atrial fibrillation/atrial flutter

History of atrial fibrillation/atrial flutter catheter ablation

Patients with cardiac implantable electronic devices

Any documented electrocardiogram showed atrial fibrillation/atrial flutter and pacing rhythm

Trial design

Treatments tested in this trial

  • AF-predict AI-ECG alert system guided management

Treatment groups

14,726 Participants
are divided into 2 treatment groups